The Indiana Clinical Trials Center | Plainfield, IN

Research site

(Unclaimed)

Location

824 Edwards Drive Suite 172, Plainfield, Indiana, United States of America

Site insights

Top conditions

Top treatments

PF-04965842

Remibrutinib

BLI1100

TMB-001

Benzoyl Peroxide

ASN002

Lebrikizumab

CB-03-01

Difamilast

Adalimumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 59 total trials

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:*...

Enrolling

Plaque Psoriasis

Drug: ESK-001

Drug: Placebo

Status recently updated

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.

Not yet enrolling

Enrolling

Moderate to Severe Genital Psoriasis

Drug: Tildrakizumab 100 mg

Drug: Placebo

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension...

Enrolling

Chronic Inducible Urticaria

Drug: Remibrutinib

Other: Placebo

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participant...

Active, not recruiting

Chronic Spontaneous Urticaria

Drug: LOU064 (blinded)

Drug: Placebo

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting

Atopic Dermatitis

Biological: Lebrikizumab

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).

Enrolling

Chronic Spontaneous Urticaria

Drug: EVO756

Drug: Placebo control

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis (UnlIMMited)

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will asse...

Active, not recruiting

Scalp Psoriasis

Genital Psoriasis

Drug: Risankizumab

Drug: Placebo for Risankizumab

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting

Dermatitis, Atopic

Drug: Abrocitinib 200 mg

Drug: Abrocitinib 100 mg